J Vet Sci.  2006 Jun;7(2):157-160. 10.4142/jvs.2006.7.2.157.

Modulatory effects of chitosan adipate on the T and B lymphocyte subsets in mice

• Obminska-Mrukowicz B
• Szczypka M
• Gaweda B

• KMID: 1059202
• DOI: http://doi.org/10.4142/jvs.2006.7.2.157

Abstract

This study examined the subsets of T lymphocytes in the thymus, spleen and mesenteric lymph nodes as well as the subsets of B lymphocytes in the spleen and mesenteric lymph nodes in mice administered chitosan adipate (20 mg/kg) intraperitoneally once or four times at 24 h intervals. The results showed that chitosan adipate decreased the percentage of immature CD4+CD8+ thymic T cells and increased the percentage of mature CD4+ and CD8+ thymocytes. The most significant stimulating effect was observed after four injections. A single exposure to chitosan adipate increased the percentage of CD4+ mesenteric lymph node cells, but four injections of the drug increased the percentage of CD4+ and CD8+ mesenteric lymph node cells. Chitosan adipate had no effect on the subset of splenic T cells. In contrast, chitosan adipate administered either once or four times increased the percentage of CD19+ splenocytes but had no effect on the percentage of CD19+ mesenteric lymph node cells. Overall, chitosan adipate induces the maturation and differentiation of thymocytes, and regulates the number of B splenic cells and lymph node T cells irrespective of the number of doses.

Keyword

B and T lymphocyte subsets; chitosan; mice

MeSH Terms

Animals
B-Lymphocyte Subsets/*drug effects/metabolism
Chitosan/*analogs&derivatives/*pharmacology
Dose-Response Relationship, Drug
Female
Immunologic Factors/pharmacology
Lymphoid Tissue/drug effects/metabolism
Male
Mice
Mice, Inbred BALB C
T-Lymphocyte Subsets/*drug effects/metabolism

Reference

1. Balicka-Ramisz A, Wojtasz-Pająk A, Ramisz A, Ligocki M. Goreckiv H, Dobrzański Z, editors. Properties of chitosan and its salts. Chemistry for Agriculture. 2002. Vol. 3. Jeseńk: Czech-Pol Trade;74–80.

2. Dawson MM. Lymphokines and Interleukins. 1991. Boca Raton: CRC Press;83–105.

3. Gery I, Gershon RK, Waksmann BH. Potentiation of cultured mouse thymocyte responses by factors released by peripheral leucocytes. J Immunol. 1971. 107:1778–1780.

4. Giri JG, Lomedico PT, Mizel SB. Studies on the synthesis and secretion of interleukin 1. I. A 33,000 molecular weight precursor for interleukin 1. J Immunol. 1985. 134:343–349.

5. Iida J, Une T, Ishihara C, Nishimura K, Tokura S, Mizukoshi N, Azuma I. Stimulation of non-specific host resistance against Sendai virus and Esherichia coli infections by chitin derivatives in mice. Vaccine. 1987. 5:270–274.

6. Kaye J, Gillis S, Mizel SB, Shevach EM, Malek TR, Dinarello CA, Lachman LB, Janeway CA Jr. Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol. 1984. 133:1339–1345.

7. Lowenthal JW, MacDonald HR. Binding and internalization of interleukin-1 by T cells. Direct evidence for high- and low-affinity classes of interleukin -1 receptor. J Exp Med. 1986. 164:1060–1074.

8. Marcinkiewicz J, Polewska A, Knapczyk J. Immunoadjuvant properties of chitosan. Arch Immunol Ther Exp (Warsz). 1991. 39:127–132.

9. Meltzer MS, Oppenheim JJ. Bidirectional amplification of macrophage-lymphocyte interactions: enhanced lymphocyte activation factor production by activated adherent mouse peritoneal cells. J Immunol. 1977. 118:77–82.

10. Moore RN, Oppenheim JJ, Farrar JJ, Carter CS Jr, Waheed A, Shadduck RK. Production of lymphocyte-activating factor (interleukin 1) by macrophages activated with colony-stimulating factors. J Immunol. 1980. 125:1302–1305.

11. Nishimura K, Ishihara C, Ukei S, Tokura S, Azuma I. Stimulation of cytokine production in mice using deacetylated chitin. Vaccine. 1986. 4:151–156.

12. Nishimura K, Nishimura S, Nishi N, Numata F, Tone Y, Tokura S, Azuma I. Adjuvant activity of chitin derivatives in mice and guinea pigs. Vaccine. 1985. 3:379–384.

13. Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological activity of chitin and its derivatives. Vaccine. 1984. 2:93–99.

14. Platter E, Gramatzki M, Röllinghoff M, Kalden JR. Lymphokines and monokines in the clinic. Immunol Today. 1986. 7:185–187.

15. Seferian PG, Martinez ML. Immune stimulating activity of two new chitosan containing adjuvant formulations. Vaccine. 2000. 19:661–668.

16. Shirakawa F, Yamashita U, Chedid M, Mizel SB. Cyclic AMP-an intracellular second messenger for interleukin 1. Proc Natl Acad Sci USA. 1988. 85:8201–8205.

17. Tizard IR. Myers MJ, Murtaugh MP, editors. Interferons. Cytokines in Animal Health and Disease. 1995. New York: Marcel Dekker;1–57.

18. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine. 2003. 21:1400–1408.

19. Weaver CT, Unanue ER. T cell induction of membrane IL-1 on macrophages. J Immunol. 1986. 137:3868–3873.

20. Westerink MA, Smithson SL, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine. 2001. 20:711–723.